Tocilizumab (brand name Actemra) is a monoclonal antibody that blocks interleukin-6 (IL-6), an inflammatory signaling molecule. It's approved for giant cell arteritis (GCA) and is used off-label for some patients with NMO.

Official website: actemra.com

Key takeaways

  • IL-6 inhibitor: blocks inflammatory signaling
  • Approved for GCA
  • Allows faster steroid tapering in GCA
  • Given as injection or IV infusion
  • Masks signs of infection: requires vigilance

Questions about your diagnosis? Contact our office

Visual guide: Tocilizumab: symptoms still matter
Educational schematic of tocilizumab treatment, masked fever and inflammation tests, and symptom-based urgent action.
Read this visual as text
Reduce inflammatory signaling: Used for GCA and off-label in some NMOSD cases; it may help reduce steroid exposure. Tests may look reassuring: Fever and ESR/CRP can be suppressed despite infection or a disease flare. Act on new symptoms: Report illness or abdominal pain promptly; call 911 for sudden vision loss.
Educational schematic: tocilizumab: symptoms still matter. Symbols summarize the article; they are not clinical images.

How It Works

IL-6 is a key driver of inflammation in conditions like GCA. By blocking IL-6, tocilizumab reduces the inflammatory process. It also allows faster tapering of steroids.

Common Uses

  • Giant cell arteritis-FDA approved
  • NMO-off-label
  • Rheumatoid arthritis

Administration

For adults with GCA, the U.S. label gives these options:

  • Under the skin: 162 mg once weekly; every-other-week dosing may be prescribed for selected patients
  • IV infusion: 6 mg/kg every four weeks, with a maximum of 600 mg per infusion
  • Treatment begins with a prescribed steroid taper; tocilizumab may continue alone after steroids are discontinued

Self-injection is possible after training. Follow your own prescription and ask the treating team about any missed dose or new infection.

Side Effects

Common

  • Injection site reactions
  • Upper respiratory infections
  • Headache
  • Elevated liver enzymes
  • Elevated cholesterol

Serious

  • Serious infections
  • Opportunistic infections, tuberculosis, invasive fungal infections, and sepsis
  • GI perforation (rare)
  • Liver damage
  • Allergic reactions

Important Warning

FDA boxed warning - serious infections: Tocilizumab can increase the risk of serious infections that may require hospitalization or can be fatal. It should not be given during an active infection, including a localized infection. Patients should be screened for tuberculosis before starting, monitored closely during treatment, and the medication is held if a serious infection, opportunistic infection, or sepsis develops.

Masks infection and GCA activity signs: Tocilizumab can suppress fever and inflammatory markers (CRP, ESR), which normally alert clinicians to infection or active inflammation. Report new cough, burning with urination, skin infection, abdominal pain, shingles-like rash, or feeling unusually ill even if you do not have a fever.

Monitoring

  • Liver function tests
  • Lipid panel
  • Complete blood count
  • TB screening before starting and monitoring for TB symptoms during therapy
  • Careful infection monitoring; hold treatment if a serious infection develops

Benefits in GCA

  • Can taper steroids faster (reducing steroid side effects)
  • Reduces risk of GCA flares
  • Long-term steroid-sparing

Pregnancy, Breastfeeding, and Vaccines

Tell your prescribing team about pregnancy plans or breastfeeding; human data are limited and treatment needs an individual benefit-risk discussion. Review vaccines before starting. Live vaccines should be avoided during treatment; ask the team about the timing of non-live vaccines.

Which Symptoms Need Action?

  • New dimming, a missing area of vision, or double vision with GCA: seek same-day emergency eye assessment, even if ESR/CRP are normal. Call 911 for sudden vision loss or associated stroke symptoms.
  • New infection symptoms or feeling unusually ill: contact the prescribing team promptly, even without fever, and ask about the next dose.
  • Severe or persistent new abdominal pain, or a marked change in bowel habits, with or without fever: seek urgent medical care because bowel perforation is a rare serious risk.

Frequently Asked Questions

Can I stop steroids?

Tocilizumab allows faster steroid tapering but usually doesn't replace steroids entirely, at least initially. Many patients can eventually stop steroids or use very low doses.

Will I still need ESR/CRP monitoring?

Tocilizumab often lowers ESR and CRP, so normal results cannot reliably rule out a flare or infection. Keep follow-up appointments and report symptoms even when your recent blood tests looked reassuring.

How long will I need this?

Duration varies. Some patients can stop after 1-2 years if GCA is in remission; others need longer treatment.

References

  1. U.S. Food and Drug Administration. ACTEMRA (tocilizumab) prescribing information.
  2. DailyMed. ACTEMRA (tocilizumab) prescribing information.